Interrogating open issues in cancer precision medicine with patient-derived xenografts

doi:10.1038/nrc.2016.140

Review

. 2017 Apr;17(4):254-268.

doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20.

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne¹, Denis G Alférez², Frédéric Amant^{3

4}, Daniela Annibali³, Joaquín Arribas^{5

6}, Andrew V Biankin⁷, Alejandra Bruna⁸, Eva Budinská⁹, Carlos Caldas⁸, David K Chang⁷, Robert B Clarke², Hans Clevers¹⁰, George Coukos¹¹, Virginie Dangles-Marie¹², S Gail Eckhardt¹³, Eva Gonzalez-Suarez¹⁴, Els Hermans³, Manuel Hidalgo¹⁵, Monika A Jarzabek¹, Steven de Jong¹⁶, Jos Jonkers¹⁷, Kristel Kemper¹⁷, Luisa Lanfrancone¹⁸, Gunhild Mari Mælandsmo¹⁹, Elisabetta Marangoni²⁰, Jean-Christophe Marine²¹, Enzo Medico²², Jens Henrik Norum¹⁹, Héctor G Palmer²³, Daniel S Peeper¹⁷, Pier Giuseppe Pelicci¹⁸, Alejandro Piris-Gimenez²³, Sergio Roman-Roman²⁰, Oscar M Rueda⁸, Joan Seoane^{5

6}, Violeta Serra²³, Laura Soucek⁵, Dominique Vanhecke¹¹, Alberto Villanueva²⁴, Emilie Vinolo²⁵, Andrea Bertotti²², Livio Trusolino²²

Affiliations

¹ EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
² EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
³ EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
⁴ The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
⁵ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
⁶ CIBERONC, 08035 Barcelona, Spain.
⁷ EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
⁸ EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
⁹ EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
¹⁰ Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
¹¹ EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
¹² EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
¹³ University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
¹⁴ EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
¹⁵ EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
¹⁶ EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
¹⁷ EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
¹⁸ EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
¹⁹ EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
²⁰ EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
²¹ EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
²² EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
²³ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
²⁴ EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
²⁵ Seeding Science SAS, 75020 Paris, France.

PMID: 28104906
DOI: 10.1038/nrc.2016.140

Free article

Review

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne et al. Nat Rev Cancer. 2017 Apr.

Free article

. 2017 Apr;17(4):254-268.

doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20.

Authors

Affiliations

¹ EurOPDX Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, Ireland.
² EurOPDX Consortium and are at the Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, University of Manchester, Manchester M20 4QL, UK.
³ EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
⁴ The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
⁵ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology, 08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
⁶ CIBERONC, 08035 Barcelona, Spain.
⁷ EurOPDX Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK.
⁸ EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, UK.
⁹ EurOPDX Consortium and is at the Institute of Biostatistics and Analyses, Faculty of Medicine, and Research Centre for Toxic Compounds in the Environment, Faculty of Science, Masarykova Univerzita, 625 00 Brno, Czech Republic.
¹⁰ Hubrecht Institute, University Medical Centre Utrecht, and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The Netherlands.
¹¹ EurOPDX Consortium and are at Lausanne Branch, Ludwig Institute for Cancer Research at the University of Lausanne, 1066 Lausanne, Switzerland.
¹² EurOPDX Consortium and is at the Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie de Paris, 75006 Paris, France.
¹³ University of Colorado Cancer Center, Aurora, Colorado 80045, USA.
¹⁴ EurOPDX Consortium and is at the Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute IDIBELL, 08908 L'Hospitalet de Llobregat, Barcelona, Spain.
¹⁵ EurOPDX Consortium and is at Beth Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, Massachusetts 02215, USA.
¹⁶ EurOPDX Consortium and is at the University Medical Centre Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.
¹⁷ EurOPDX Consortium and are at The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
¹⁸ EurOPDX Consortium and are at the Department of Experimental Oncology, European Institiute of Oncology, 20139 Milan, Italy.
¹⁹ EurOPDX Consortium and are at Oslo University Hospital, Institute for Cancer Research, 0424 Oslo, Norway.
²⁰ EurOPDX Consortium and are at Institut Curie, PSL Research University, Translational Research Department, 75005 Paris, France.
²¹ EurOPDX Consortium and is at the Laboratory for Molecular Cancer Biology, Department of Oncology, Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 Leuven, Belgium.
²² EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
²³ EurOPDX Consortium and are at the Vall d'Hebron Institute of Oncology and CIBERONC, 08035 Barcelona, Spain.
²⁴ EurOPDX Consortium and is at the Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 L'Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
²⁵ Seeding Science SAS, 75020 Paris, France.

PMID: 28104906
DOI: 10.1038/nrc.2016.140

Erratum in

Interrogating open issues in cancer medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. Online ahead of print. Nat Rev Cancer. 2017. PMID: 28912576

Abstract

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

PubMed Disclaimer

Cited by

Current methods in translational cancer research.
Lee MW, Miljanic M, Triplett T, Ramirez C, Aung KL, Eckhardt SG, Capasso A. Lee MW, et al. Cancer Metastasis Rev. 2021 Mar;40(1):7-30. doi: 10.1007/s10555-020-09931-5. Epub 2020 Sep 14. Cancer Metastasis Rev. 2021. PMID: 32929562 Free PMC article. Review.
Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer.
Huang H, Pan Y, Huang J, Zhang C, Liao Y, Du Q, Qin S, Chen Y, Tan H, Chen M, Xu M, Xia M, Liu Y, Li J, Liu T, Zou Q, Zhou Y, Yuan L, Wang W, Liang Y, Pan CY, Liu J, Yao S. Huang H, et al. iScience. 2023 Oct 12;26(11):108198. doi: 10.1016/j.isci.2023.108198. eCollection 2023 Nov 17. iScience. 2023. PMID: 38026204 Free PMC article.
Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis.
Zang J, Ye K, Fei Y, Zhang R, Chen H, Zhuang G. Zang J, et al. Front Oncol. 2021 May 26;11:696716. doi: 10.3389/fonc.2021.696716. eCollection 2021. Front Oncol. 2021. PMID: 34123863 Free PMC article. Review.
X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.
Carlet M, Schmelz K, Vergalli J, Herold T, Senft D, Jurinovic V, Hoffmann T, Proba J, Weichert N, Junghanß C, Roth M, Eschenburg G, Barz M, Henze G, Eckert C, Eggert A, Zuber J, Hundsdoerfer P, Jeremias I. Carlet M, et al. EMBO Mol Med. 2023 Jan 11;15(1):e14557. doi: 10.15252/emmm.202114557. Epub 2022 Nov 23. EMBO Mol Med. 2023. PMID: 36416169 Free PMC article.
KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition.
Hu B, Cheng JW, Hu JW, Li H, Ma XL, Tang WG, Sun YF, Guo W, Huang A, Zhou KQ, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Yang XR. Hu B, et al. J Cancer. 2019 Jun 24;10(17):3914-3925. doi: 10.7150/jca.31448. eCollection 2019. J Cancer. 2019. PMID: 31417635 Free PMC article.

See all "Cited by" articles

References

1. Clin Cancer Res. 2014 Aug 15;20(16):4251-61 - PubMed
1. Cancer Res. 2016 Oct 1;76(19):5798-5809 - PubMed
1. Nat Rev Drug Discov. 2013 Aug;12(8):569 - PubMed
1. Blood. 2011 Sep 22;118(12):3426-35 - PubMed
1. Oncogene. 2016 Jan 21;35(3):290-300 - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Clin Cancer Res. 2014 Aug 15;20(16):4251-61 - PubMed

[2] Clin Cancer Res. 2014 Aug 15;20(16):4251-61 - PubMed

[3] Cancer Res. 2016 Oct 1;76(19):5798-5809 - PubMed

[4] Cancer Res. 2016 Oct 1;76(19):5798-5809 - PubMed

[5] Nat Rev Drug Discov. 2013 Aug;12(8):569 - PubMed

[6] Nat Rev Drug Discov. 2013 Aug;12(8):569 - PubMed

[7] Blood. 2011 Sep 22;118(12):3426-35 - PubMed

[8] Blood. 2011 Sep 22;118(12):3426-35 - PubMed

[9] Oncogene. 2016 Jan 21;35(3):290-300 - PubMed

[10] Oncogene. 2016 Jan 21;35(3):290-300 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Affiliations

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Authors

Affiliations

Erratum in

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources